Palliative Chemotherapy for Pancreatic Malignancies

Surgical Clinics of North America

Volumn 90, Issue 2, 2010, Pages 365-375

  Mehta, Sharmila P ^a  

^a Gibbs Cancer Center   (United States)

Author keywords

Chemotherapy; Management; Palliative; Pancreatic cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DNA; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CHEMOTHERAPY INDUCED EMESIS; CHOLANGITIS; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DNA SYNTHESIS INHIBITION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; FATIGUE; HUMAN; HYPONATREMIA; INFECTION; MONOTHERAPY; NAUSEA; NEUROPATHY; NEUROTOXICITY; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; STOMATITIS; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; QUALITY OF LIFE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIROLIMUS;

EID: 77950818346     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2009.12.005     Document Type: Review

References (47)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. National Comprehensive Cancer Network (NCCN) Available at:, Accessed November 3, 2009. http://www.nccn.org/professionals/physcian_gls/f_guidelines.asp.
3. Heinemann V., Boeck S., Hinke A., et al. Meta-analysis of randomized trials: evaluation of benefit form gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008, 8:82.
4. Wolff R. Chemotherapy for pancreatic cancer: from metastatic disease to adjuvant therapy. Cancer J 2007, 13(3):175-181.
5. Chu E., DeVita V. 5-fluorouracil: cancer chemotherapy drug manual 2009 2009, Jones and Bartlett, Sudbury (MA), p. 179-84.
6. Cartwright T.H., Cohn A., Varkey J., et al. Phase II study of oral capecitabine on patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002, 20(1):160-164.
7. Sultana A., Smith C.T., Cunningham D., et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007, 25(18):2607-2615.
8. Yip D., Karapetis C., Strickland A., et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2006, (3). CD002093.
9. Ridwelski K., Fahlke J., Kuhn R., et al. Multicenter phase I/II study using combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma. Eur J Surg Oncol 2006, 32(3):297-302.
10. Jacobs A.D., Otero H., Picozzi V.J., et al. Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma. Cancer Invest 2004, 22(4):505-514.
11. Schneider B.P., Ganjoo K.N., Seitz D.E., et al. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 2003, 65(3):218-223.
12. Skeel R. Gemcitabine: handbook of cancer chemotherapy 2003, Lippincott, Williams, and Wilkins, Philadelphia, p. 116-7. 6th edition.
13. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15(6):2403-2413.
14. Tempero M., Plunkett W., Van Haperen Ruiz, et al. Randomized phase II comparison of dose intense gemcitabine: thirty minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003, 21(18):3402-3408.
15. Louvet C., Labianca R., Hammel P., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer; results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005, 23(15):3509-3516.
16. Poplin E., Feng Y., Berlin J., et al. Phase III randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009, 27(23):3778-3785.
17. Chu E., DeVita V. Capecitabine: cancer chemotherapy drug manual 2009 2009, Jones and Bartlett, Sudbury (MA), p. 64-70.
18. Stathopoulos G.P., Syrigos K., Aravantinos G., et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006, 95(5):587-592.
19. Heinemann V., Quietzsh D., Gieseler F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006, 24(24):3946-3952.
20. Saif M.W., Kim R. Role of platinum agents in the management of advanced pancreatic cancer. Expert Opin Pharmacother 2007, 8(16):2719-2727.
21. Heinemann V., Labianca R., Hinke A., et al. Increased survival using platinum analog combined with gemcitabine as compared to single agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007, 18(10):1652-1659.
22. Hermann R., Bodoky G., Ruhstaller B., et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer. A randomized multicenter, phase III trial of the Swiss Group for Clinical Cancer research and the Central European Cooperative Oncology Group. J Clin Oncol 2007, 25:2212-2217.
23. Cunningham D., Chau I., Stocken D., et al. Phase III randomized comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer Suppl 2005, 3:4.
24. Nieto J., Grossbard M., Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty?. Oncologist 2008, 13:562-576.
25. Mahalingam D., Kelly K., Swords R., et al. Emerging drugs in the treatment of pancreatic cancer. Expert Opin Emerg Drugs 2009, 14(2):311-328.
26. Mahalingam D., Giles F. Challenges in developing targeted therapies for pancreatic adnenocarcinoma. Expert Opin Ther Targets 2008, 12(11):1389-1401.
27. Chu E., DeVita V. Erlotinib: cancer chemotherapy drug manual 2009 2009, Jones and Bartlett, Sudbury (MA), p. 149-55.
28. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25(15):1960-1966.
29. Senderowicz A., Johnson J., Sridhara R., et al. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park). (FDA Approval Summary) 2007, 21(14):1696-1706.
30. Epelbaum R, Schnaider J, Gluzman A, et al. Erlotinib as a single agent therapy in patients with advanced pancreatic cancer. Presented at the 2007 ASCO GI Cancer Symposium. Orlando (FL), January 19-21, 2007.
31. Danovi S.A., Wong H.H., Lemoine N.R. Targeted therapies for pancreatic cancer. Br Med Bull 2008, 87:97-130.
32. Kindler H.L., Niedzwiecki D., Hollis D., et al. Cancer and Leukemia group B A Double blind, placebo controlled randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in pts with advanced pancreatic cancer (PC); a preliminary analysis of CALGB. J Clin Oncol 2007, 25(18s). (meeting abstracts) [abstract 4508].
33. Kindler H.L., Friberg G., Singh D.A., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005, 23:8033-8040.
34. Van Cutsem E., Ververnne W.L., Bennouna J., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in metastatic pancreatic cancer. J Clin Oncol 2009, 27(13):2231-2237.
35. Vervenne W., Bennouna Y., Humblet S., et al. A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer [abstract 4507]. J Clin Oncol 2008, 26(15S). 2008 ASCO Annual Meeting Proceedings.
36. Wallace J.A., Locker G., Nattam S., et al. Sorafenib plus gemcitabine for advanced pancreatic cancer (PC): a phase II trial of the University of Chicago Phase II Consortium. 2007 ASCO Annual Meeting Proceedings Part I [abstract 4608]. J Clin Oncol 2007, 25(18S (Suppl 20)).
37. Michaelson M.D., Schwarzberg A., Ryan D.P., et al. Phase I dose findings study of sunitinib (SU) in combination with gemcitabine (G) in patients (pts) with advanced solid tumors [abstract 14522]. Clin Oncol 2008, 26(Suppl 20).
38. Kindler H.L., Bylow K.A., Hoschester G., et al. A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC) [abstract 4502]. ASCO Annual Meeting Proceedings. J Clin Oncol 2006, 26(15S).
39. El Kamar F., Grossbard M., Kozuch P. Metastatic pancreatic cancer; emerging strategies in chemotherapy and palliative care. Oncologist 2003, 8:18-34.
40. Wolpin B., Hezel A., Abrams T., et al. Oral mTOR Inhibitor Everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009, 27(2):193-198.
41. Javle M.M., Xiong H., Reddy S., et al. Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: the results of two prospective studies [abstract 4621]. ASCO Annual Meeting Proceedings. J Clin Oncol 2009, 27(15S).
42. Phillip P.A., Benedetti C., Fenoglio-Preiser M., et al. Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC): SWOG S0205 study [abstract LBA4509]. J Clin Oncol 2007, 25(18S). Annual Meeting Proceedings.
43. Chu E., DeVita V. Cetuximab: cancer chemotherapy drug manual 2009 2009, Jones and Bartlett, Sudbury (MA), p. 77-82.
44. Almhanna K., Kim R. Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?. Oncology 2008, 22(10):1176-1183.
45. Pelzer U., Stieler J., Roll L., et al. Second-line therapy in refractory pancreatic cancer: results of a phase II study. Onkologie 2009, 32(3):99-102.
46. Cereda S., Reni M. Weekly docetaxel as salvage therapy in patients with gemcitabine refractory metastatic pancreatic cancer. J Chemother 2008, 20(4):509-512.
47. Ko A.H., Dito E., Schillinger B., et al. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest 2008, 26(1):47-52.